Brief: Regen Biopharma Prepares Response For FDA Regarding Its Orphan Drug Application For HemaXellerate
16/09/2025 13:21
Sept 16 (Reuters) - Regen BioPharma Inc RGBP.PK: REGEN BIOPHARMA PREPARES RESPONSE FOR FDA REGARDING ITS ORPHAN DRUG APPLICATION FOR HEMAXELLERATE Source text: ID:nGNX31MDn7 Further company coverage: RGBP.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regen BioPharma
See all newsBrief: Regen Biopharma Prepares Response For FDA Regarding Its Orphan Drug Application For HemaXellerate
Brief: Regen Biopharma Expands Vision For Phase 1 Clinical Trial Of Hemaxellerate
Brief: Regen Biopharma, Inc. Receives First Phase Of Confirmatory Study
Brief: Regen Biopharma Files Provisional Patent On Car-T Cell Capable Of Attracting And Educating Naïve T Cells
Brief: Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics